Reduces copayments and coinsurance for asthma inhalers covered by certain health benefits plans.
Impact
The reduction in costs for asthma inhalers will apply to all relevant insurance policies delivered, issued, or renewed in the state. The law mandates that these plans cannot impose deductibles on inhaler purchases, ensuring that cost-sharing is limited to the new cap of $35. This measure is expected to provide financial relief to those with asthma by making necessary medications more affordable and accessible, thus improving health outcomes for affected individuals.
Summary
Senate Bill S291 addresses the out-of-pocket costs for patients prescribed asthma inhalers under certain health benefits plans in New Jersey. Specifically, the bill amends prior legislation to reduce the maximum copayment and coinsurance for a 30-day supply of prescription asthma inhalers from $50 to $35. The coverage provided by this bill applies to a wide range of health insurance entities, including individual and group hospital service corporations, medical service corporations, health maintenance organizations, and the State Health Benefits Commission.
Contention
Discussions around S291 could involve concerns regarding how this legislative change may affect insurance premiums and the fiscal responsibilities of health insurance providers. Some stakeholders argue that while lowering copayments is beneficial to patients, it may lead to increased costs for insurers, potentially resulting in higher premiums for consumers overall. Furthermore, there could be debates around the scope of medications covered under such health policies, with advocates pushing for broader inclusion of essential therapies beyond just asthma inhalers.